Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
Episode
26 min
Read time
2 min
Topics
Investing, Fundraising & VC, Leadership
AI-Generated Summary
Key Takeaways
- ✓Oral SERD market size: Estrogen receptor-positive, HER2-negative breast cancer represents approximately 70% of all breast cancers, making oral SERDs a massive commercial opportunity. Two products already hold approval — Menarini's Elacestrant (2023) and Lilly's Imlunestrant (2025) — with 11 pipeline assets competing across second-line, first-line, and adjuvant treatment settings.
- ✓PROTAC milestone watch: Arvinas and Pfizer's vepdegestrant carries a June 2025 PDUFA date and could become the first approved PROTAC in any disease. Unlike indirect-mechanism oral SERDs, PROTACs directly label the estrogen receptor for degradation via E3 ligase linkage, potentially achieving deeper receptor knockdown in the second-line setting.
- ✓Differentiation strategy for crowded SERD field: With second-line indications becoming crowded, companies pursuing first-line and adjuvant settings — including Roche's giredestrant and AstraZeneca's camizestrant — gain competitive separation. Blood-brain-barrier penetration for brain metastasis coverage represents another concrete differentiation axis, with NRADI's SIRDU brain metastasis data expected in Q4.
- ✓FDA accelerated approval risk for orphan drugs: FDA issued a complete response letter to DISC Medicine based on biomarker clinical relevance skepticism, continuing a pattern of rejecting biomarker-based accelerated approvals in rare diseases. Investors and developers should treat accelerated approval pathways for orphan indications as materially less reliable under current FDA leadership, with Vinay Prasad directly involved in CDER decisions beyond his CBER role.
- ✓mRNA vaccine pipeline vulnerability: FDA's refusal to file Moderna's mRNA flu vaccine application creates a structural disincentive for mRNA influenza vaccine development. This is particularly consequential for pandemic preparedness: during an avian influenza outbreak, egg-based manufacturing faces supply constraints from poultry culling, making mRNA the only scalable rapid-response platform available.
What It Covers
BioCentury This Week episode 350 examines the oral SERD landscape, covering 11 pipeline assets competing for dominance in estrogen receptor-positive breast cancer, plus FDA's refusal to file Moderna's flu vaccine application and a complete response letter issued to DISC Medicine for an orphan disease therapy.
Key Questions Answered
- •Oral SERD market size: Estrogen receptor-positive, HER2-negative breast cancer represents approximately 70% of all breast cancers, making oral SERDs a massive commercial opportunity. Two products already hold approval — Menarini's Elacestrant (2023) and Lilly's Imlunestrant (2025) — with 11 pipeline assets competing across second-line, first-line, and adjuvant treatment settings.
- •PROTAC milestone watch: Arvinas and Pfizer's vepdegestrant carries a June 2025 PDUFA date and could become the first approved PROTAC in any disease. Unlike indirect-mechanism oral SERDs, PROTACs directly label the estrogen receptor for degradation via E3 ligase linkage, potentially achieving deeper receptor knockdown in the second-line setting.
- •Differentiation strategy for crowded SERD field: With second-line indications becoming crowded, companies pursuing first-line and adjuvant settings — including Roche's giredestrant and AstraZeneca's camizestrant — gain competitive separation. Blood-brain-barrier penetration for brain metastasis coverage represents another concrete differentiation axis, with NRADI's SIRDU brain metastasis data expected in Q4.
- •FDA accelerated approval risk for orphan drugs: FDA issued a complete response letter to DISC Medicine based on biomarker clinical relevance skepticism, continuing a pattern of rejecting biomarker-based accelerated approvals in rare diseases. Investors and developers should treat accelerated approval pathways for orphan indications as materially less reliable under current FDA leadership, with Vinay Prasad directly involved in CDER decisions beyond his CBER role.
- •mRNA vaccine pipeline vulnerability: FDA's refusal to file Moderna's mRNA flu vaccine application creates a structural disincentive for mRNA influenza vaccine development. This is particularly consequential for pandemic preparedness: during an avian influenza outbreak, egg-based manufacturing faces supply constraints from poultry culling, making mRNA the only scalable rapid-response platform available.
Notable Moment
BioCentury's Washington editor, who has covered FDA for over 30 years, publicly called on CEOs of major pharmaceutical companies to demand Vinay Prasad's removal from FDA — a step he described as unprecedented in his career, citing staff harassment complaints, routine override of experienced scientists, and unpredictable regulatory decisions.
Episode Transcript
The oral SIRD field is expanding. As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. We'll discuss the landscape for oral SIRDS on this week's BioCentury This Week podcast, and we'll check-in on The US regulatory environment in the wake of a refusal to file for a Moderna vaccine by FDA and a setback at FDA for an accelerated approval for an orphan drug from DISC medicine. I'm Jeff Cranmer, host of the BioCentury This Week podcast and executive editor here at BioCentury. And today I'm joined by podcast regulars, Steve Austin, who is our longtime Washington editor, and Lauren Martz, who heads up all of our product development coverage. But first, we're excited here at BioCentury to introduce a new exclusive opportunity for our subscribers. It's launching at the BioCentury Bay Helix East West Summit in Seoul. In a matter of a few weeks, you'll be able to step inside the BioSentry Lounge, a dedicated space designed to connect, recharge, and inspire conversation among industry leaders. You can experience unique networking moments, insider insights, and a place to unwind between sessions. Don't wait. Check out more at biocenturylounge.com. And if you haven't registered yet, join us in Seoul. It's gonna be a great chance to check out the Korean biotech ecosystem, and we will have investors from around the globe. We'll have biotechs from China. We'll have investors from Singapore. We'll have a lot of investors from Japan on a panel that I'll be moderating on the Japanese biotech ecosystem. So Good. I I just have to say that lounge sounds so cool. Are you gonna have lounge music? Are people gonna be re wearing loungewear? You know? I I really hope I'm gonna wear loungewear. I think that sounds really, really awesome, Steve. And I'm also hoping that they're gonna have some, like, you know, massage chairs and and maybe some, some delicious Korean food like some mandu or or perhaps a little, kimchi treats of some sort. I don't know, Steve. Why don't you join us this time around? I would I would love to. I I would go all the way to Korea for a lounge. It's gonna be good. And, late night, I'm told, we'll be doing, some norabang, which is the Korean answer to Japan's karaoke craze, and, I'm sure it will be a soju fueled experience. I'm gonna be practicing all my Ringo Starr songs. That's that's kinda my my wheelhouse there. Alright. Let's get to it. Next generation estrogen receptor degraders, SIRDS, aim to differentiate on depth of pathway suppression, modality, and which treatment settings they can own. Lindsey Martin did a deep dive, one of our new analysis decks that are really cool. And, Lauren, you edited the piece. You've been following the space for ages now. What's what's new? Thanks, Jeff. Yeah. Lindsay did a great job on this very comprehensive deck of what's happening in the oral …
Get the full transcript (3,974 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 23-minute episode.
Get BioCentury This Week summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from BioCentury This Week
Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
Sep 9 · 35 min
a16z Podcast
The System Behind Self-Driving: Waymo’s Dmitri Dolgov
Apr 17
More from BioCentury This Week
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
Sep 1 · 35 min
Biotech Bulls & Breakthroughs
Biopharma Industry: Insights from BioSpace Senior Editor Annalee Armstrong
Aug 1
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links. As an Amazon Associate, SignalCast earns from qualifying purchases.
Products
- CamizestrantBy guest
by AstraZeneca
“companies pursuing first-line and adjuvant settings — including Roche's giredestrant and AstraZeneca's camizestrant — gain competitive separation.”
- ElacestrantBy guest
by Menarini
“Two products already hold approval — Menarini's Elacestrant (2023) and Lilly's Imlunestrant (2025)”
- VepdegestrantBy guest
by Arvinas and Pfizer
“Arvinas and Pfizer's vepdegestrant carries a June 2025 PDUFA date and could become the first approved PROTAC in any disease.”
- ImlunestrantBy guest
by Eli Lilly
“Two products already hold approval — Menarini's Elacestrant (2023) and Lilly's Imlunestrant (2025)”
- GiredestrantBy guest
by Roche
“With second-line indications becoming crowded, companies pursuing first-line and adjuvant settings — including Roche's giredestrant and AstraZeneca's camizestrant”
More from BioCentury This Week
We summarize every new episode. Want them in your inbox?
Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
Ep. 384 - Back to School Special: The global FIH trials race
Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick
Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA
Similar Episodes
Related episodes from other podcasts
a16z Podcast
Apr 17
The System Behind Self-Driving: Waymo’s Dmitri Dolgov
Biotech Bulls & Breakthroughs
Aug 1
Biopharma Industry: Insights from BioSpace Senior Editor Annalee Armstrong
The AI Breakdown
Sep 11
What to Use the Latest AI Tools For
How I AI
Sep 2
Grok Bot vs. OpenClaw: How I replaced my entire agent stack
In Good Company with Nicolai Tangen
Aug 28
Friday Wrap-Up: A Hedge Fund Legend and Reflections on the Global AI Race
Explore Related Topics
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Investing & Markets Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into BioCentury This Week.
Every Monday, we deliver AI summaries of the latest episodes from BioCentury This Week and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime